High-density lipoprotein: A new therapeutic target for glucose intolerance?

Circulation

Volumn 128, Issue 22, 2013, Pages 2349-2350

  Mortensen, Stefan P ^a   Boushel, Robert ^b  

^a Rigshospitalet   (Denmark)

^b SWEDISH SCHOOL OF SPORT AND HEALTH SCIENCES   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEIN; FIBROBLAST GROWTH FACTOR 21; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; LIPOPROTEIN; GLUCOSE BLOOD LEVEL;

ADIPOSE TISSUE; BODY COMPOSITION; CHOLESTEROL BLOOD LEVEL; COMPARATIVE STUDY; EDITORIAL; ENDURANCE TRAINING; ENERGY METABOLISM; EXERCISE; FATTY ACID OXIDATION; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE INTOLERANCE; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; HOMEOSTASIS; IN VIVO STUDY; INSULIN RESISTANCE; KNOCKOUT MOUSE; LEAN BODY WEIGHT; MITOCHONDRIAL RESPIRATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PHOSPHOLIPID VESICLE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SUBUNIT; RESPIRATION CONTROL; SKELETAL MUSCLE; WILD TYPE; ANIMAL; HYPERGLYCEMIA; MALE; METABOLISM;

ANIMALS; BLOOD GLUCOSE; GLUCOSE INTOLERANCE; HYPERGLYCEMIA; LIPOPROTEINS, HDL; MALE; MUSCLE, SKELETAL;

EID: 84888596278     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.113.006345     Document Type: Editorial

References (13)

1. Gordon DJ, Rifkind BM. High-density lipoprotein-The clinical implications of recent studies. N Engl J Med. 1989;321:1311-1316
2. Navab M, Hama SY, Cooke CJ, Anantharamaiah GM, Chaddha M, Jin L, Subbanagounder G, Faull KF, Reddy ST, Miller NE, Fogelman AM. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: Step 1. J Lipid Res. 2000;41:1481-1494
3. Navab M, Hama SY, Anantharamaiah GM, Hassan K, Hough GP, Watson AD, Reddy ST, Sevanian A, Fonarow GC, Fogelman AM. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: Steps 2 and 3. J Lipid Res. 2000;41:1495-1508
4. Barter PJ, Nicholls S, Rye KA, Anantharamaiah GM, Navab M, Fogelman AM. Antiinflammatory properties of HDL. Circ Res. 2004;95:764-772
5. Calkin AC, Drew BG, Ono A, Duffy SJ, Gordon MV, Schoenwaelder SM, Sviridov D, Cooper ME, Kingwell BA, Jackson SP. Reconstituted high-density lipoprotein attenuates platelet function in individuals with type 2 diabetes mellitus by promoting cholesterol efflux. Circulation. 2009;120:2095-2104
6. Yuhanna IS, Zhu Y, Cox BE, Hahner LD, Osborne-Lawrence S, Lu P, Marcel YL, Anderson RG, Mendelsohn ME, Hobbs HH, Shaul PW. Highdensity lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase. Nat Med. 2001;7:853-857
7. Fleisher LN, Tall AR, Witte LD, Miller RW, Cannon PJ. Stimulation of arterial endothelial cell prostacyclin synthesis by high density lipoproteins. J Biol Chem. 1982;257:6653-6655
8. Drew BG, Duffy SJ, Formosa MF, Natoli AK, Henstridge DC, Penfold SA, Thomas WG, Mukhamedova N, de Courten B, Forbes JM, Yap FY, Kaye DM, van Hall G, Febbraio MA, Kemp BE, Sviridov D, Steinberg GR, Kingwell BA. High-density lipoprotein modulates glucose metabolism in patients with type 2 diabetes mellitus. Circulation. 2009;119:2103-2111
9. Brunham LR, Kruit JK, Pape TD, Timmins JM, Reuwer AQ, Vasanji Z, Marsh BJ, Rodrigues B, Johnson JD, Parks JS, Verchere CB, Hayden MR. Beta-cell ABCA1 influences insulin secretion, glucose homeostasis and response to thiazolidinedione treatment. Nat Med. 2007;13:340-347
10. Han R, Lai R, Ding Q, Wang Z, Luo X, Zhang Y, Cui G, He J, Liu W, Chen Y. Apolipoprotein A-I stimulates AMP-Activated protein kinase and improves glucose metabolism. Diabetologia. 2007;50:1960-1968
11. Lehti M, Donelan E, Abplanalp W, Al-Massadi O, Habegger KM, Weber J, Ress C, Mansfeld J, Somvanshi S, Trivedi C, Keuper M, Ograjsek T, Strisse C, Cucuruz S, Pfluger PT, Krishna R, Gordon SM, Silva GD, Luquet S, Castel J, Martinez S, D'Alessio D, Davidson WS, Hofmann SM. High-density lipoprotein maintains skeletal muscle function by modulating cellular respiration in mice. Circulation. 2013;128:2364-2371
12. Kharitonenkov A, Shiyanova TL, Koester A, Ford AM, Micanovic R, Galbreath EJ, Sandusky GE, Hammond LJ, Moyers JS, Owens RA, Gromada J, Brozinick JT, Hawkins ED, Wroblewski VJ, Li DS, Mehrbod F, Jaskunas SR, Shanafelt AB. FGF-21 as a novel metabolic regulator. J Clin Invest. 2005;115:1627-1635
13. Hellsten Y, Nyberg M, Jensen LG, Mortensen SP. Vasodilator interactions in skeletal muscle blood flow regulation. J Physiol. 2012;590(Pt 24):6297-6305